Page last updated: 2024-11-05

2,4,6-triiodophenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11862
CHEMBL ID81721
SCHEMBL ID338137
MeSH IDM0183435

Synonyms (46)

Synonym
2,4,6-triiodo-phenol
2,4,6-triiodo-phenol(tip)
CHEMBL81721 ,
triiodophenol
2,4,6-trijodfenol
9rb2r81a7u ,
unii-9rb2r81a7u
AKOS009031508
EN300-19379
phenol,4,6-triiodo-
609-23-4
2,6-triiodophenol
nsc2594
wln: qr bi di fi
nsc-2594
phenol, 2,4,6-triiodo-
einecs 210-186-7
2,4,6-trijodfenol [czech]
brn 2046861
nsc 2594
2,4,6-triiodophenol ,
inchi=1/c6h3i3o/c7-3-1-4(8)6(10)5(9)2-3/h1-2,10
2,4,6-triiodophenol, 97%
T0452
bdbm50301374
A832958
FT-0609879
AM20040842
SCHEMBL338137
dtxsid8022080 ,
tox21_303909
NCGC00356970-01
dtxcid602080
cas-609-23-4
AC-22931
F8889-6052
mfcd00002179
2,4,6-triiodophenol, certified reference material, tracecert(r)
CS-0106873
am-24
D76670
Q27272970
AS-57147
HY-W073687
SY048671
Z104473672

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The assay was applied to pharmacokinetic studies in dog and horse plasma and different dog tissues for tissue distribution profiles toxicological and metabolic studies."( High-performance liquid chromatography analysis of Bobel-24 in biological samples for pharmacokinetic, metabolic and tissue distribution studies.
Arroyo, C; Bonal, J; García-Capdevila, L; López-Calull, C; Molins-Pujol, AM; Pompermayer, S, 1998
)
0.3
" First, a model capable of dealing with the nonlinearity in its pharmacokinetic profile was built, and then it was combined with a pharmacodynamic model previously established with data from earlier phase I trials."( Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor.
Antonijoan, RM; Barbanoj, MJ; Garrido, MJ; Trocóniz, IF; Valle, M; Zsolt, I, 2006
)
0.33

Bioavailability

ExcerptReferenceRelevance
" Relative bioavailability was independent of the decrease in the amount of enzyme."( Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor.
Antonijoan, RM; Barbanoj, MJ; Garrido, MJ; Trocóniz, IF; Valle, M; Zsolt, I, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
"The aim of this study was to explore the possibility of achieving a practical dosing regimen for 2,4,6-triiodophenol (AM-24), a new leukotriene B4 (LTB4) synthesis inhibitor."( Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor.
Antonijoan, RM; Barbanoj, MJ; Garrido, MJ; Trocóniz, IF; Valle, M; Zsolt, I, 2006
)
0.55
"Simulations have shown that steady-state conditions eliciting 90% of maximal LTB4 synthesis inhibition can be reached after 3 weeks during an oral treatment with AM-24 administered at the dosage of 500 mg once daily."( Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor.
Antonijoan, RM; Barbanoj, MJ; Garrido, MJ; Trocóniz, IF; Valle, M; Zsolt, I, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency48.96623.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency66.67120.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency65.72080.000714.592883.7951AID1259369; AID1259392
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency14.52030.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency54.48270.001022.650876.6163AID1224838
progesterone receptorHomo sapiens (human)Potency30.63790.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency68.58960.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency22.59500.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency64.86010.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency68.58960.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency61.13060.000229.305416,493.5996AID1259244; AID1259248
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency36.36390.154917.870243.6557AID1346877; AID1346891
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency61.13060.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency61.13060.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TransthyretinHomo sapiens (human)IC50 (µMol)3.20000.16004.292110.0000AID448548
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID521552Antiparasitic activity against Cryptosporidium parvum infected in human HCT-8 cells assessed as growth inhibition at 2 mg/ml after 48 hrs2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID521564Antimicrobial activity against Cryptosporidium parvum infected in SCID mouse assessed as decrease in oocyst shedding at 125 mg/kg/day, po for 2 weeks and measured 3 to 7 days after treatment2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID521555Antiparasitic activity against Cryptosporidium parvum infected into human HCT-8 cells assessed as growth inhibition at 22 uM after 48 hrs2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID230635KPCB/ K352 ratio of the compound1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
A theoretical study of the binding of polychlorinated biphenyls (PCBs), dibenzodioxins, and dibenzofuran to human plasma prealbumin.
AID161305Relative binding affinity against prealbumin in competition binding assay and expressed as relative to L-T4 (100)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Molecular interactions of toxic chlorinated dibenzo-p-dioxins and dibenzofurans with thyroxine binding prealbumin.
AID521562Antimicrobial activity against Cryptosporidium parvum infected in HCT8 cells assessed as growth inhibition rate at 22 to 90 uM after 48 hrs2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID521563Antimicrobial activity against Cryptosporidium parvum infected in SCID mouse assessed as decrease in oocyst shedding at 125 mg/kg/day, po for 2 weeks and measured every 3 days during treatment2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID521560Antiparasitic activity against Cryptosporidium parvum infected into human HCT-8 cells assessed as growth inhibition at 2 mg/ml after 48 hrs2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID448551Displacement of [125I]thyroxin from TTR2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors.
AID521554Antiparasitic activity against Cryptosporidium parvum sprozoites assessed as growth inhibition at 90 uM after 48 hrs2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID521558Antimicrobial activity against Cryptosporidium parvum DE infected in HCT8 cells assessed as growth inhibition at 90 uM after 24 hrs2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID161430Displacement of [125I]thyroxin from human plasma prealbumin.1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
A theoretical study of the binding of polychlorinated biphenyls (PCBs), dibenzodioxins, and dibenzofuran to human plasma prealbumin.
AID521565Antimicrobial activity against Cryptosporidium parvum infected in SCID mouse assessed as decrease in oocyst shedding at 250 mg/kg/day, po for 2 weeks and measured 3 to 7 days after treatment2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID521556Antiparasitic activity against Cryptosporidium parvum infected into human HCT-8 cells assessed as growth inhibition at 45 uM after 48 hrs2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID521559Antiparasitic activity against Cryptosporidium parvum infected into human HCT-8 cells assessed as growth inhibition at 90 uM after 48 hrs2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID448549Inhibition of TTR mediated fibrillogenesis assessed as acid-induced protein aggregation turbidity after 1.5 hrs by turbidimetric assay relative to control2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors.
AID521557Cytotoxicity against human HCT8 cells assessed as cell viability by MTT assay2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID448548Inhibition of TTR mediated fibrillogenesis assessed as acid-induced protein aggregation turbidity after 1.5 hrs by turbidimetric assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors.
AID210552Relative binding affinity for nuclear receptor from rat liver compared to thyroxine (T4) as KA(comp)/KA(T41987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID161431Thyroxine binding constant on human plasma prealbumin.1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
A theoretical study of the binding of polychlorinated biphenyls (PCBs), dibenzodioxins, and dibenzofuran to human plasma prealbumin.
AID521561Antimicrobial activity against Cryptosporidium parvum infected in HCT8 cells assessed as decrease in parasite count at 22 to 90 uM after 48 hrs2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID521553Antimicrobial activity against Cryptosporidium parvum infected in HCT8 cells assessed as growth inhibition at 90 uM pretreated for 30 min before infection measured after 48 hrs2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
AID161435Relative binding affinity for thyroxin binding prealbumin (TBPA) from rat liver compared to thyroxine (T4) as KA(comp)/KA(T4)1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID1898642Displacement of [125I]-T4 from human recombinant TTR expressed in Escherichia coli BL21(DE3) Star by gamma spectrometric analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (13.04)18.7374
1990's3 (13.04)18.2507
2000's7 (30.43)29.6817
2010's6 (26.09)24.3611
2020's4 (17.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.97 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.35%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]